J&J Ortho Tri-Cyclen Lo "approvable"
Executive Summary
Final labeling under negotiation for Ortho-McNeil's oral contraceptive Ortho Tri-Cyclen Lo, J&J's Poon says. The 25 mcg low-dose ethinyl estradiol/norgestimate formulation received an "approvable" letter June 25
You may also be interested in...
Tri-Cyclen Lo Clears FDA; Ortho-McNeil Patches Up Contraceptive Line
Ortho-McNeil is ready to launch the second pillar in its contraceptive product line defense following the approval of Tri-Cyclen Lo (norgestimate/ethinyl estradiol) Aug. 22
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011